A Randomized, Placebo-Controlled Study of Romosozumab for the Treatment of Hip Fractures.
Journal
The Journal of bone and joint surgery. American volume
ISSN: 1535-1386
Titre abrégé: J Bone Joint Surg Am
Pays: United States
ID NLM: 0014030
Informations de publication
Date de publication:
15 Apr 2020
15 Apr 2020
Historique:
pubmed:
25
1
2020
medline:
11
11
2020
entrez:
25
1
2020
Statut:
ppublish
Résumé
Romosozumab is a bone-forming antibody that increases bone formation and decreases bone resorption. We conducted a double-blinded, randomized, phase-2, dose-finding trial to evaluate the effect of romosozumab on the clinical outcomes of open reduction and internal fixation of intertrochanteric or femoral neck hip fractures. Patients (55 to 94 years old) were randomized 2:3:3:3 to receive 3 subcutaneous injections of romosozumab (70, 140, or 210 mg) or a placebo postoperatively on day 1 and weeks 2, 6, and 12. The primary end point was the difference in the mean timed "Up & Go" (TUG) score over weeks 6 to 20 for romosozumab versus placebo. Additional end points included the time to radiographic evidence of healing and the score on the Radiographic Union Scale for Hip (RUSH). A total of 332 patients were randomized: 243 to receive romosozumab (70 mg, n = 60; 140 mg, n = 93; and 210 mg, n = 90) and 89 to receive a placebo. Although TUG scores improved during the study, they did not differ significantly between the romosozumab and placebo groups over weeks 6 to 20 (p = 0.198). The median time to radiographic evidence of healing was 16.4 to 16.9 weeks across treatment groups. The RUSH scores improved over time across treatment groups but did not differ significantly between the romosozumab and placebo groups. The overall safety and tolerability profile of romosozumab was comparable with that of the placebo. Romosozumab did not improve the fracture-healing-related clinical and radiographic outcomes in the study population. Therapeutic Level I. See Instructions for Authors for a complete description of levels of evidence.
Sections du résumé
BACKGROUND
BACKGROUND
Romosozumab is a bone-forming antibody that increases bone formation and decreases bone resorption. We conducted a double-blinded, randomized, phase-2, dose-finding trial to evaluate the effect of romosozumab on the clinical outcomes of open reduction and internal fixation of intertrochanteric or femoral neck hip fractures.
METHODS
METHODS
Patients (55 to 94 years old) were randomized 2:3:3:3 to receive 3 subcutaneous injections of romosozumab (70, 140, or 210 mg) or a placebo postoperatively on day 1 and weeks 2, 6, and 12. The primary end point was the difference in the mean timed "Up & Go" (TUG) score over weeks 6 to 20 for romosozumab versus placebo. Additional end points included the time to radiographic evidence of healing and the score on the Radiographic Union Scale for Hip (RUSH).
RESULTS
RESULTS
A total of 332 patients were randomized: 243 to receive romosozumab (70 mg, n = 60; 140 mg, n = 93; and 210 mg, n = 90) and 89 to receive a placebo. Although TUG scores improved during the study, they did not differ significantly between the romosozumab and placebo groups over weeks 6 to 20 (p = 0.198). The median time to radiographic evidence of healing was 16.4 to 16.9 weeks across treatment groups. The RUSH scores improved over time across treatment groups but did not differ significantly between the romosozumab and placebo groups. The overall safety and tolerability profile of romosozumab was comparable with that of the placebo.
CONCLUSIONS
CONCLUSIONS
Romosozumab did not improve the fracture-healing-related clinical and radiographic outcomes in the study population.
LEVEL OF EVIDENCE
METHODS
Therapeutic Level I. See Instructions for Authors for a complete description of levels of evidence.
Identifiants
pubmed: 31977817
doi: 10.2106/JBJS.19.00790
pmc: PMC7508283
pii: 00004623-202004150-00009
doi:
Substances chimiques
Antibodies, Monoclonal
0
Bone Density Conservation Agents
0
romosozumab
3VHF2ZD92J
Types de publication
Clinical Trial, Phase II
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
693-702Références
J Clin Pharmacol. 2014 Feb;54(2):168-78
pubmed: 24272917
J Rehabil Med. 2003 Mar;35(2):76-83
pubmed: 12691337
J Musculoskelet Neuronal Interact. 2013 Jun;13(2):178-84
pubmed: 23728104
Phys Ther. 2002 Feb;82(2):128-37
pubmed: 11856064
N Engl J Med. 2014 Jan 30;370(5):412-20
pubmed: 24382002
J Bone Miner Res. 2017 May;32(5):1040-1051
pubmed: 28019683
Orthop Surg. 2015 May;7(2):132-7
pubmed: 26033994
J Bone Joint Surg Am. 2013 Feb 6;95(3):200-8
pubmed: 23389782
Clin Orthop Relat Res. 2016 May;474(5):1234-44
pubmed: 26932738
J Am Geriatr Soc. 2004 Aug;52(8):1343-8
pubmed: 15271124
Clin Orthop Relat Res. 2016 Jun;474(6):1396-404
pubmed: 26728521
Osteoporos Int. 2004 Nov;15(11):897-902
pubmed: 15490120
J Bone Miner Res. 2011 May;26(5):1012-21
pubmed: 21542004
J Bone Miner Res. 2011 Jan;26(1):19-26
pubmed: 20593411
Biometrics. 1978 Dec;34(4):541-54
pubmed: 373811
J Orthop Trauma. 2013 Sep;27(9):e213-9
pubmed: 23287749
BMC Musculoskelet Disord. 2013 Feb 25;14:70
pubmed: 23442540
Medicine (Baltimore). 2016 May;95(19):e3626
pubmed: 27175673
N Engl J Med. 2016 Oct 20;375(16):1532-1543
pubmed: 27641143
J Bone Joint Surg Am. 2016 Nov 16;98(22):1868-1878
pubmed: 27852903
J Am Geriatr Soc. 1991 Feb;39(2):142-8
pubmed: 1991946
J Bone Joint Surg Am. 2015 Dec 2;97(23):1905-12
pubmed: 26631990
J Orthop Res. 2014 Aug;32(8):997-1005
pubmed: 24782158
Int Orthop. 2015 Jul;39(7):1405-10
pubmed: 25876225
Injury. 2015 Aug;46(8):1425-8
pubmed: 26175420
Skeletal Radiol. 2013 Aug;42(8):1079-88
pubmed: 23564001
Int Orthop. 2002;26(6):365-9
pubmed: 12466870
Phys Ther. 2007 Jan;87(1):24-30
pubmed: 17142643
Calcif Tissue Int. 2013 Jan;92(1):42-9
pubmed: 23135744
N Engl J Med. 2017 Oct 12;377(15):1417-1427
pubmed: 28892457
Am J Epidemiol. 2009 Nov 15;170(10):1290-9
pubmed: 19808632